Pyridoxamine Supplement Sale Should Cease Following IND Filing - Petition
This article was originally published in The Tan Sheet
Executive Summary
Dietary supplements containing pyridoxamine should be removed from the market following the filing of an investigational new drug application for the ingredient, according to a citizen petition filed July 29
You may also be interested in...
BioStratum Challenges Affidavit Asserting Pre-1994 Pyridoxamine Product
Hopeful pyridoxamine drug marketer BioStratum is skeptical of an affidavit submitted to FDA by Jarrow Formulas as evidence of the pre-1994 sale of pyridoxamine in supplements
BioStratum Challenges Affidavit Asserting Pre-1994 Pyridoxamine Product
Hopeful pyridoxamine drug marketer BioStratum is skeptical of an affidavit submitted to FDA by Jarrow Formulas as evidence of the pre-1994 sale of pyridoxamine in supplements
BioStratum Challenges Affidavit Asserting Pre-1994 Pyridoxamine Product
Hopeful pyridoxamine drug marketer BioStratum is skeptical of an affidavit submitted to FDA by Jarrow Formulas as evidence of the pre-1994 sale of pyridoxamine in supplements